Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required)

The summary for the Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required): The HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network seeks to evaluate innovative approaches for overcoming barriers and reducing failures in the cervical cancer screening and treatment cascade for women living with HIV. The proposed multicenter network will conduct pragmatic clinical trials to evaluate the effectiveness of clinically proven interventions in intended-use settings with a goal to optimize the cervical cancer screening, management, and precancer treatment cascade for women living with HIV. These trials will focus on the health care continuum for secondary cervical cancer prevention, i.e., increasing screening uptake, improving management of screen positives, facilitating precancer treatment access, and optimizing precancer treatments. Data from these trials will be used to provide the necessary evidence to refine clinical practice guidelines and inform public health policy with a goal to generate crucial actionable evidence for improving cervical cancer prevention implementation programs. Six-to-eight UG1 cooperative agreement mechanism-funded Clinical Sites, led by clinical investigators and/or clinicians, will provide a pluripotent clinical infrastructure to conduct/implement multiple prevention clinical trials through the CASCADE network and interface with network grantees during concept and protocol development to provide insights and input on clinical significance and study feasibility.

Federal Grant Title:	Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-CA-22-051
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.393, 93.395, 93.399
CFDA Descriptions:	Information not provided
Current Application Deadline:	December 28th, 2022
Original Application Deadline:	December 28th, 2022
Posted Date:	October 3rd, 2022
Creation Date:	October 3rd, 2022
Archive Date:	February 2nd, 2023
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	October 3rd, 2022

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-051.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Early-Stage Development of Informatics Technologies for Cancer Research and Management (U0...; • Advanced Development of Informatics Technologies for Cancer Research and Management (U24 C...; • Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Cli...; • NCI Community Oncology Research Program (NCORP) Academic Community Sites (UG1 Clinical Tri...; • NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Require...; • Pilot Studies in Pancreatic Cancer; • Cancer Prevention Research Small Grant Program; • Molecular Targets for Nutrients in Prostate Cancer Prevention
More Grants from the National Institutes of Health: • Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Radiologi...; • Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required); • Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Clinical Trial Not ...; • Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required); • Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P5...